HLS Therapeutics Inc.
4.33CAD
+0.1800 (+4.34%)
Computing valuation metrics…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on HLS.TO.
Valuation
P/E (TTM)
—
P/E (Forward)
—
EV/EBITDA
9.25x
EV/Revenue
2.88x
P/S (TTM)
2.38x
P/B
2.43x
FCF Yield
12.85%
Dividend Yield
0.00%
Gross Margin
80.95%
Operating Margin
-8.02%
Net Margin
-15.24%
Peer Comparison — Drug Manufacturers - Specialty & Generic
No comparable peers tracked yet.
Peers are Drug Manufacturers - Specialty & Generic names quoted in CAD, so every figure in the table means the same thing. More appear as they are traded or watchlisted on the platform.
Subject metrics from SEC filings where available; peer metrics from cached market data.